Skip to content
Search

Latest Stories

Power outage disrupts GPhC registration assessment for 3 hours

Power outage disrupts GPhC registration assessment for 3 hours
GPhC registration assessment for summer 2024 required candidates to have satisfactorily completed 39 weeks of training on or before 3 May 2024 

On Thursday (27) the Chief Operating Officer at the General Pharmaceutical Council (GPhC), Jonathan Bennetts, reported a major power cut at London Highbury test centre that caused major delays in the examination process.

London Highbury test centre is amongst 87 centres where the GPhC's registration assessment for summer 2024 took place which required candidates to have completed 39 weeks of training on or before May 3 and with satisfactory 39 weeks of training progress report.


Bennetts reported that approximately 2,700 candidates sat for the registration assessment  when at one of the centres "unexpected power outage caused a three-hour delay."

"Around seventy candidates at the London Highbury test centre were unable to start Part 2 of the assessment at the scheduled time of 2:15 PM," Bennetts stated.

The unexpected power outage caused a three-hour delay, during which candidates were kept informed and provided with refreshments.

Additional GPhC representatives were dispatched to the centre to support the affected candidates.

The power was restored after three hours, allowing the candidates to commence Part 2 of the examination.

Essential checks were conducted to ensure everything was in order before resuming the assessment.

Bennetts acknowledged the inconvenience caused by the delay, emphasising the GPhC's awareness of the stress it might have induced among the candidates.

"We fully understand the impact that the power cut may have had on these candidates and the stress this will have caused," he said.

The GPhC is taking proactive steps to address the issue by reaching out to the affected candidates via email.

In their communication, they are extending their apologies and providing an explanation of the candidates' options.

Additionally, the GPhC is encouraging candidates to contact them if they wish to discuss these options further.

Despite the significant disruption at the London Highbury test centre, Bennetts reported that the rest of the 86 centres conducting the registration assessment experienced no significant issues.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less